Review



us optum s de identified clinformatics data mart database cdm  (Optum Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Optum Inc us optum s de identified clinformatics data mart database cdm
    Us Optum S De Identified Clinformatics Data Mart Database Cdm, supplied by Optum Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/de-identified+clinformatics%C2%AE+data+mart+(optum+cdm)/clinformatics+data+database+mart/pm40830742-6309-9-10
    Average 86 stars, based on 1 article reviews
    us optum s de identified clinformatics data mart database cdm - by Bioz Stars, 2026-09
    86/100 stars

    Images

    Related Articles

    other:

    Article Title: Comparison of cardiovascular outcomes between once-weekly semaglutide and dulaglutide in adults with type 2 diabetes and established atherosclerotic cardiovascular disease in the United States.
    Article Snippet: This was a retrospective, observational cohort study using administrative claims data from Optum®'s de-identified Clinformatics Data Mart (Optum CDM) from 1 January 2007 through 30 September 2024, under a target-trial emulation framework.

    Article Title: The timing of genetic testing and healthcare costs associated with the diagnostic journey of inherited retinal disease.
    Article Snippet: This retrospective, observational cohort study used de-identified patient-level data from the Optum® Clinformatics® Data Mart (CDM) database.

    Article Title: The Potential of Non-ablative Erbium (YAG) Laser Treatment for Complications After Midurethral Sling Surgery: A Narrative Review
    Article Snippet: Lee et al. analyzed the Optum® de-identified Clinformatics® Data Mart (CDM) for women aged 18-64 years and the Centers for Medicare and Medicaid Services (CMS) Medicare 5% Sample for women aged 65 years or older to examine trends in the surgical management of female urinary incontinence from 2004 to 2013.

    Article Title: Patterns of new glucagon‐like peptide‐1 receptor agonist use in patients with type 2 diabetes during 2014–2019 from a US database: prescriber and patient characteristics
    Article Snippet: This is a descriptive study of retrospective data from Optum® de-identified Clinformatics® Data Mart (CDM) Database (2004–2020), a claims database based on filled prescriptions for people enrolled in large commercial and Medicare Advantage health plans in the US.

    Derivative Assay:

    Article Title: Cardiovascular events, mortality, and incident type 2 diabetes in patients with metabolic dysfunction-associated steatohepatitis: a claims-based analysis of commercial and Medicare Advantage enrollees.
    Article Snippet: .. This noninterventional, retrospective cohort study used Optum®’s de-identified Clinformatics® Data Mart (CDM) database, which is derived from administrative health claims data for enrollees of large commercial and Medicare Advantage health plans in the US. ..



    Similar Products

    us optum s de identified clinformatics data mart database cdm  (Optum Inc)
    86
    Optum Inc us optum s de identified clinformatics data mart database cdm
    Us Optum S De Identified Clinformatics Data Mart Database Cdm, supplied by Optum Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/de-identified+clinformatics%C2%AE+data+mart+(optum+cdm)/clinformatics+data+database+mart/pm40830742-6309-9-10
    Average 86 stars, based on 1 article reviews
    us optum s de identified clinformatics data mart database cdm - by Bioz Stars, 2026-09
    86/100 stars
    		  Buy from Supplier
    de-identified clinformatics® data mart (optum cdm)  (Optum Inc)
    90
    Optum Inc de-identified clinformatics® data mart (optum cdm)
    De Identified Clinformatics® Data Mart (Optum Cdm), supplied by Optum Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/de-identified+clinformatics%C2%AE+data+mart+(optum+cdm)/de+identified+clinformatics+data+mart+database/pm40570006-58-12-15
    Average 90 stars, based on 1 article reviews
    de-identified clinformatics® data mart (optum cdm) - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    cdm optum’s de-identified clinformatics data mart database  (Optum Inc)
    90
    Optum Inc cdm optum’s de-identified clinformatics data mart database
    Patient attrition flowchart. Patient attrition flowcharts for A CDM and B Komodo Healthcare Map analyses. Patient numbers for the semaglutide and DPP-4i groups can be found on the left and right side of each panel, respectively. a Inverse probability of treatment weighting was applied using stabilized average treatment effect weights derived by conducting a logistic regression including the variables age, sex, race/ethnicity, geographic region, index year, Charlson Comorbidity Index, diabetes complications severity index, type of <t>ASCVD</t> history, glucose-lowering therapy, HbA1c, body mass index, and number of all-cause hospitalizations in the baseline period and 60 days before the index date. ASCVD <t>atherosclerotic</t> cardiovascular disease, CDM Optum’s de-identified Clinformatics ® Data Mart Database, DPP - 4i dipeptidyl peptidase 4 inhibitor, HbA1c hemoglobin A1c, T1D type 1 diabetes, T2D type 2 diabetes
    Cdm Optum’s De Identified Clinformatics Data Mart Database, supplied by Optum Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/de-identified+clinformatics%C2%AE+data+mart+(optum+cdm)/de+identified+clinformatics+data+mart+database/pmc11794941-129-0-5
    Average 90 stars, based on 1 article reviews
    cdm optum’s de-identified clinformatics data mart database - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    cdm optum’s de-identified clinformatics® data mart database  (Optum Inc)
    90
    Optum Inc cdm optum’s de-identified clinformatics® data mart database
    Patient attrition flowchart. Patient attrition flowcharts for A CDM and B Komodo Healthcare Map analyses. Patient numbers for the semaglutide and DPP-4i groups can be found on the left and right side of each panel, respectively. a Inverse probability of treatment weighting was applied using stabilized average treatment effect weights derived by conducting a logistic regression including the variables age, sex, race/ethnicity, geographic region, index year, Charlson Comorbidity Index, diabetes complications severity index, type of <t>ASCVD</t> history, glucose-lowering therapy, HbA1c, body mass index, and number of all-cause hospitalizations in the baseline period and 60 days before the index date. ASCVD <t>atherosclerotic</t> cardiovascular disease, CDM Optum’s de-identified Clinformatics ® Data Mart Database, DPP - 4i dipeptidyl peptidase 4 inhibitor, HbA1c hemoglobin A1c, T1D type 1 diabetes, T2D type 2 diabetes
    Cdm Optum’s De Identified Clinformatics® Data Mart Database, supplied by Optum Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/de-identified+clinformatics%C2%AE+data+mart+(optum+cdm)/de+identified+clinformatics+data+mart+database/pm39688779-170-0-5
    Average 90 stars, based on 1 article reviews
    cdm optum’s de-identified clinformatics® data mart database - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    cdm, optum’s de-identified clinformatics® data mart data base  (Optum Inc)
    90
    Optum Inc cdm, optum’s de-identified clinformatics® data mart data base
    Patient attrition flowchart. Patient attrition flowcharts for A CDM and B Komodo Healthcare Map analyses. Patient numbers for the semaglutide and DPP-4i groups can be found on the left and right side of each panel, respectively. a Inverse probability of treatment weighting was applied using stabilized average treatment effect weights derived by conducting a logistic regression including the variables age, sex, race/ethnicity, geographic region, index year, Charlson Comorbidity Index, diabetes complications severity index, type of <t>ASCVD</t> history, glucose-lowering therapy, HbA1c, body mass index, and number of all-cause hospitalizations in the baseline period and 60 days before the index date. ASCVD <t>atherosclerotic</t> cardiovascular disease, CDM Optum’s de-identified Clinformatics ® Data Mart Database, DPP - 4i dipeptidyl peptidase 4 inhibitor, HbA1c hemoglobin A1c, T1D type 1 diabetes, T2D type 2 diabetes
    Cdm, Optum’s De Identified Clinformatics® Data Mart Data Base, supplied by Optum Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/de-identified+clinformatics%C2%AE+data+mart+(optum+cdm)/de+identified+clinformatics+data+mart+database/pm39688779-36-1-5
    Average 90 stars, based on 1 article reviews
    cdm, optum’s de-identified clinformatics® data mart data base - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    cdm optum’s de-identified clinformatics ® data mart database  (Optum Inc)
    90
    Optum Inc cdm optum’s de-identified clinformatics ® data mart database
    Study design. CCAE <t>IBM</t> <t>MarketScan</t> Commercial Database, CMCOI coexisting medical conditions of interest, <t>MDCR</t> IBM MarketScan <t>Medicare</t> <t>Supplemental</t> Database, Optum CDM Optum’s de-identified Clinformatics ® Data Mart Database, NSAIDs non-steroidal anti-inflammatory drugs, OA osteoarthritis,
    Cdm Optum’s De Identified Clinformatics ® Data Mart Database, supplied by Optum Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/de-identified+clinformatics%C2%AE+data+mart+(optum+cdm)/de+identified+clinformatics+data+mart+database/pmc11021340-115-8-14
    Average 90 stars, based on 1 article reviews
    cdm optum’s de-identified clinformatics ® data mart database - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    optum’s de-identified clinformatics data mart database optum cdm  (Optum Inc)
    90
    Optum Inc optum’s de-identified clinformatics data mart database optum cdm
    Study design. CCAE IBM MarketScan Commercial Database, CMCOI coexisting medical conditions of interest, MDCR IBM MarketScan Medicare Supplemental Database, Optum CDM Optum’s de-identified <t>Clinformatics</t> ® Data Mart Database, NSAIDs non-steroidal anti-inflammatory drugs, OA osteoarthritis,
    Optum’s De Identified Clinformatics Data Mart Database Optum Cdm, supplied by Optum Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/de-identified+clinformatics%C2%AE+data+mart+(optum+cdm)/de+identified+clinformatics+data+mart+database/pmc11021340-22-17-22
    Average 90 stars, based on 1 article reviews
    optum’s de-identified clinformatics data mart database optum cdm - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    optum's de-identified clinformatics® data mart database (optum® cdm)  (Optum Inc)
    90
    Optum Inc optum's de-identified clinformatics® data mart database (optum® cdm)
    Study design. CCAE IBM MarketScan Commercial Database, CMCOI coexisting medical conditions of interest, MDCR IBM MarketScan Medicare Supplemental Database, Optum CDM Optum’s de-identified <t>Clinformatics</t> ® Data Mart Database, NSAIDs non-steroidal anti-inflammatory drugs, OA osteoarthritis,
    Optum's De Identified Clinformatics® Data Mart Database (Optum® Cdm), supplied by Optum Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/de-identified+clinformatics%C2%AE+data+mart+(optum+cdm)/de+identified+clinformatics+data+mart+database/pm37828803-7478-32-37
    Average 90 stars, based on 1 article reviews
    optum's de-identified clinformatics® data mart database (optum® cdm) - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Patient attrition flowchart. Patient attrition flowcharts for A CDM and B Komodo Healthcare Map analyses. Patient numbers for the semaglutide and DPP-4i groups can be found on the left and right side of each panel, respectively. a Inverse probability of treatment weighting was applied using stabilized average treatment effect weights derived by conducting a logistic regression including the variables age, sex, race/ethnicity, geographic region, index year, Charlson Comorbidity Index, diabetes complications severity index, type of ASCVD history, glucose-lowering therapy, HbA1c, body mass index, and number of all-cause hospitalizations in the baseline period and 60 days before the index date. ASCVD atherosclerotic cardiovascular disease, CDM Optum’s de-identified Clinformatics ® Data Mart Database, DPP - 4i dipeptidyl peptidase 4 inhibitor, HbA1c hemoglobin A1c, T1D type 1 diabetes, T2D type 2 diabetes

    Journal: Diabetes Therapy

    Article Title: Cardiovascular Events in Adults with Type 2 Diabetes and ASCVD Initiating Once-Weekly Semaglutide vs DPP-4is in the USA

    doi: 10.1007/s13300-024-01678-4

    Figure Lengend Snippet: Patient attrition flowchart. Patient attrition flowcharts for A CDM and B Komodo Healthcare Map analyses. Patient numbers for the semaglutide and DPP-4i groups can be found on the left and right side of each panel, respectively. a Inverse probability of treatment weighting was applied using stabilized average treatment effect weights derived by conducting a logistic regression including the variables age, sex, race/ethnicity, geographic region, index year, Charlson Comorbidity Index, diabetes complications severity index, type of ASCVD history, glucose-lowering therapy, HbA1c, body mass index, and number of all-cause hospitalizations in the baseline period and 60 days before the index date. ASCVD atherosclerotic cardiovascular disease, CDM Optum’s de-identified Clinformatics ® Data Mart Database, DPP - 4i dipeptidyl peptidase 4 inhibitor, HbA1c hemoglobin A1c, T1D type 1 diabetes, T2D type 2 diabetes

    Article Snippet: ASCVD atherosclerotic cardiovascular disease, CDM Optum’s de-identified Clinformatics ® Data Mart Database, CI confidence interval, DPP - 4i dipeptidyl peptidase 4 inhibitor, T2D type 2 diabetes In Komodo Healthcare Map, incidence rates for stroke, MI, and their composite were − 5.41, − 1.65, and − 7.01 per 1000 person-years lower, respectively, in the semaglutide group compared with the DPP-4i group.

    Techniques: Derivative Assay

    Clinical outcomes in adults with T2D and ASCVD who initiated semaglutide or DPP-4is. Weighted incidence rates, hazard ratios, and cumulative incidence curves of clinical outcomes comparing adults with T2D and ASCVD who initiated semaglutide vs DPP-4is in A CDM and B Komodo Healthcare Map. *Indicates statistical significance ( P < 0.05). ASCVD atherosclerotic cardiovascular disease, CDM Optum’s de-identified Clinformatics ® Data Mart Database, CI confidence interval, DPP - 4i dipeptidyl peptidase 4 inhibitor, T2D type 2 diabetes

    Journal: Diabetes Therapy

    Article Title: Cardiovascular Events in Adults with Type 2 Diabetes and ASCVD Initiating Once-Weekly Semaglutide vs DPP-4is in the USA

    doi: 10.1007/s13300-024-01678-4

    Figure Lengend Snippet: Clinical outcomes in adults with T2D and ASCVD who initiated semaglutide or DPP-4is. Weighted incidence rates, hazard ratios, and cumulative incidence curves of clinical outcomes comparing adults with T2D and ASCVD who initiated semaglutide vs DPP-4is in A CDM and B Komodo Healthcare Map. *Indicates statistical significance ( P < 0.05). ASCVD atherosclerotic cardiovascular disease, CDM Optum’s de-identified Clinformatics ® Data Mart Database, CI confidence interval, DPP - 4i dipeptidyl peptidase 4 inhibitor, T2D type 2 diabetes

    Article Snippet: ASCVD atherosclerotic cardiovascular disease, CDM Optum’s de-identified Clinformatics ® Data Mart Database, CI confidence interval, DPP - 4i dipeptidyl peptidase 4 inhibitor, T2D type 2 diabetes In Komodo Healthcare Map, incidence rates for stroke, MI, and their composite were − 5.41, − 1.65, and − 7.01 per 1000 person-years lower, respectively, in the semaglutide group compared with the DPP-4i group.

    Techniques:

    Health care utilization in adults with T2D and ASCVD who initiated semaglutide or DPP-4is. Weighted descriptive statistics and rate ratios of health care utilization comparing adults with T2D and ASCVD who initiated semaglutide vs DPP-4is in A CDM and B Komodo Healthcare Map. *Indicates statistical significance ( P < 0.05). ASCVD atherosclerotic cardiovascular disease, CDM Optum’s de-identified Clinformatics ® Data Mart Database, CI confidence interval, DPP - 4i dipeptidyl peptidase 4 inhibitor, ER emergency room, IP inpatient, OP outpatient, T2D type 2 diabetes

    Journal: Diabetes Therapy

    Article Title: Cardiovascular Events in Adults with Type 2 Diabetes and ASCVD Initiating Once-Weekly Semaglutide vs DPP-4is in the USA

    doi: 10.1007/s13300-024-01678-4

    Figure Lengend Snippet: Health care utilization in adults with T2D and ASCVD who initiated semaglutide or DPP-4is. Weighted descriptive statistics and rate ratios of health care utilization comparing adults with T2D and ASCVD who initiated semaglutide vs DPP-4is in A CDM and B Komodo Healthcare Map. *Indicates statistical significance ( P < 0.05). ASCVD atherosclerotic cardiovascular disease, CDM Optum’s de-identified Clinformatics ® Data Mart Database, CI confidence interval, DPP - 4i dipeptidyl peptidase 4 inhibitor, ER emergency room, IP inpatient, OP outpatient, T2D type 2 diabetes

    Article Snippet: ASCVD atherosclerotic cardiovascular disease, CDM Optum’s de-identified Clinformatics ® Data Mart Database, CI confidence interval, DPP - 4i dipeptidyl peptidase 4 inhibitor, T2D type 2 diabetes In Komodo Healthcare Map, incidence rates for stroke, MI, and their composite were − 5.41, − 1.65, and − 7.01 per 1000 person-years lower, respectively, in the semaglutide group compared with the DPP-4i group.

    Techniques:

    Cost outcomes in adults with T2D and ASCVD who initiated semaglutide or DPP-4is. Weighted descriptive statistics and rate ratios of medical costs comparing adults with T2D and ASCVD who initiated semaglutide vs DPP-4is in A CDM and B Komodo Healthcare Map. *Indicates statistical significance ( P < 0.05). ASCVD, atherosclerotic cardiovascular disease; CDM, Optum’s de-identified Clinformatics ® Data Mart Database, CI confidence interval, DPP - 4i dipeptidyl peptidase 4 inhibitor, IP inpatient, T2D type 2 diabetes

    Journal: Diabetes Therapy

    Article Title: Cardiovascular Events in Adults with Type 2 Diabetes and ASCVD Initiating Once-Weekly Semaglutide vs DPP-4is in the USA

    doi: 10.1007/s13300-024-01678-4

    Figure Lengend Snippet: Cost outcomes in adults with T2D and ASCVD who initiated semaglutide or DPP-4is. Weighted descriptive statistics and rate ratios of medical costs comparing adults with T2D and ASCVD who initiated semaglutide vs DPP-4is in A CDM and B Komodo Healthcare Map. *Indicates statistical significance ( P < 0.05). ASCVD, atherosclerotic cardiovascular disease; CDM, Optum’s de-identified Clinformatics ® Data Mart Database, CI confidence interval, DPP - 4i dipeptidyl peptidase 4 inhibitor, IP inpatient, T2D type 2 diabetes

    Article Snippet: ASCVD atherosclerotic cardiovascular disease, CDM Optum’s de-identified Clinformatics ® Data Mart Database, CI confidence interval, DPP - 4i dipeptidyl peptidase 4 inhibitor, T2D type 2 diabetes In Komodo Healthcare Map, incidence rates for stroke, MI, and their composite were − 5.41, − 1.65, and − 7.01 per 1000 person-years lower, respectively, in the semaglutide group compared with the DPP-4i group.

    Techniques:

    Journal: Diabetes Therapy

    Article Title: Cardiovascular Events in Adults with Type 2 Diabetes and ASCVD Initiating Once-Weekly Semaglutide vs DPP-4is in the USA

    doi: 10.1007/s13300-024-01678-4

    Figure Lengend Snippet:

    Article Snippet: ASCVD atherosclerotic cardiovascular disease, CDM Optum’s de-identified Clinformatics ® Data Mart Database, CI confidence interval, DPP - 4i dipeptidyl peptidase 4 inhibitor, T2D type 2 diabetes In Komodo Healthcare Map, incidence rates for stroke, MI, and their composite were − 5.41, − 1.65, and − 7.01 per 1000 person-years lower, respectively, in the semaglutide group compared with the DPP-4i group.

    Techniques:

    Study design. CCAE IBM MarketScan Commercial Database, CMCOI coexisting medical conditions of interest, MDCR IBM MarketScan Medicare Supplemental Database, Optum CDM Optum’s de-identified Clinformatics ® Data Mart Database, NSAIDs non-steroidal anti-inflammatory drugs, OA osteoarthritis,

    Journal: Drugs & Aging

    Article Title: Patterns of Comorbidities and Prescribing and Dispensing of Non-steroidal Anti-inflammatory Drugs (NSAIDs) Among Patients with Osteoarthritis in the USA: Real-World Study

    doi: 10.1007/s40266-024-01108-x

    Figure Lengend Snippet: Study design. CCAE IBM MarketScan Commercial Database, CMCOI coexisting medical conditions of interest, MDCR IBM MarketScan Medicare Supplemental Database, Optum CDM Optum’s de-identified Clinformatics ® Data Mart Database, NSAIDs non-steroidal anti-inflammatory drugs, OA osteoarthritis,

    Article Snippet: CCAE IBM MarketScan Commercial Database, Coxibs COX-2 inhibitors, MDCR IBM MarketScan Medicare Supplemental Database, Optum CDM Optum’s de-identified Clinformatics ® Data Mart Database Among patients with OA with CMCOI, post-OA diagnosis prescribing and dispensing of coxibs increased to a greater extent in the CCAE (+1.0%) and Optum CDM (+0.9%) databases than the MDCR (+0.2%) database (Fig. ).

    Techniques:

    Demographic characteristics of the study OA population stratified by CMCOI status

    Journal: Drugs & Aging

    Article Title: Patterns of Comorbidities and Prescribing and Dispensing of Non-steroidal Anti-inflammatory Drugs (NSAIDs) Among Patients with Osteoarthritis in the USA: Real-World Study

    doi: 10.1007/s40266-024-01108-x

    Figure Lengend Snippet: Demographic characteristics of the study OA population stratified by CMCOI status

    Article Snippet: CCAE IBM MarketScan Commercial Database, Coxibs COX-2 inhibitors, MDCR IBM MarketScan Medicare Supplemental Database, Optum CDM Optum’s de-identified Clinformatics ® Data Mart Database Among patients with OA with CMCOI, post-OA diagnosis prescribing and dispensing of coxibs increased to a greater extent in the CCAE (+1.0%) and Optum CDM (+0.9%) databases than the MDCR (+0.2%) database (Fig. ).

    Techniques:

    Coexisting medical conditions of interest (CMCOI) prevalence in the osteoarthritis population. CMCOIs are not mutually exclusive. In particular, one patient can have multiple CMCOIs. CCAE IBM MarketScan Commercial Database, MDCR IBM MarketScan Medicare Supplemental Database, Optum CDM Optum’s de-identified Clinformatics ® Data Mart Database

    Journal: Drugs & Aging

    Article Title: Patterns of Comorbidities and Prescribing and Dispensing of Non-steroidal Anti-inflammatory Drugs (NSAIDs) Among Patients with Osteoarthritis in the USA: Real-World Study

    doi: 10.1007/s40266-024-01108-x

    Figure Lengend Snippet: Coexisting medical conditions of interest (CMCOI) prevalence in the osteoarthritis population. CMCOIs are not mutually exclusive. In particular, one patient can have multiple CMCOIs. CCAE IBM MarketScan Commercial Database, MDCR IBM MarketScan Medicare Supplemental Database, Optum CDM Optum’s de-identified Clinformatics ® Data Mart Database

    Article Snippet: CCAE IBM MarketScan Commercial Database, Coxibs COX-2 inhibitors, MDCR IBM MarketScan Medicare Supplemental Database, Optum CDM Optum’s de-identified Clinformatics ® Data Mart Database Among patients with OA with CMCOI, post-OA diagnosis prescribing and dispensing of coxibs increased to a greater extent in the CCAE (+1.0%) and Optum CDM (+0.9%) databases than the MDCR (+0.2%) database (Fig. ).

    Techniques:

    Proportion a of the osteoarthritis population in CCAE, MDCR, and Optum CDM databases with 0, 1, 2, 3 or at least 4 CMCOI

    Journal: Drugs & Aging

    Article Title: Patterns of Comorbidities and Prescribing and Dispensing of Non-steroidal Anti-inflammatory Drugs (NSAIDs) Among Patients with Osteoarthritis in the USA: Real-World Study

    doi: 10.1007/s40266-024-01108-x

    Figure Lengend Snippet: Proportion a of the osteoarthritis population in CCAE, MDCR, and Optum CDM databases with 0, 1, 2, 3 or at least 4 CMCOI

    Article Snippet: CCAE IBM MarketScan Commercial Database, Coxibs COX-2 inhibitors, MDCR IBM MarketScan Medicare Supplemental Database, Optum CDM Optum’s de-identified Clinformatics ® Data Mart Database Among patients with OA with CMCOI, post-OA diagnosis prescribing and dispensing of coxibs increased to a greater extent in the CCAE (+1.0%) and Optum CDM (+0.9%) databases than the MDCR (+0.2%) database (Fig. ).

    Techniques:

    Prescribing and dispensing of non-steroidal anti-inflammatory drugs among patients with osteoarthritis, stratified by coexisting medical conditions of interest (CMCOI) status and database. CCAE IBM MarketScan Commercial Database, MDCR IBM MarketScan Medicare Supplemental Database, Optum CDM Optum’s de-identified Clinformatics ® Data Mart Database

    Journal: Drugs & Aging

    Article Title: Patterns of Comorbidities and Prescribing and Dispensing of Non-steroidal Anti-inflammatory Drugs (NSAIDs) Among Patients with Osteoarthritis in the USA: Real-World Study

    doi: 10.1007/s40266-024-01108-x

    Figure Lengend Snippet: Prescribing and dispensing of non-steroidal anti-inflammatory drugs among patients with osteoarthritis, stratified by coexisting medical conditions of interest (CMCOI) status and database. CCAE IBM MarketScan Commercial Database, MDCR IBM MarketScan Medicare Supplemental Database, Optum CDM Optum’s de-identified Clinformatics ® Data Mart Database

    Article Snippet: CCAE IBM MarketScan Commercial Database, Coxibs COX-2 inhibitors, MDCR IBM MarketScan Medicare Supplemental Database, Optum CDM Optum’s de-identified Clinformatics ® Data Mart Database Among patients with OA with CMCOI, post-OA diagnosis prescribing and dispensing of coxibs increased to a greater extent in the CCAE (+1.0%) and Optum CDM (+0.9%) databases than the MDCR (+0.2%) database (Fig. ).

    Techniques:

    Prescribing and dispensing of non-steroidal anti-inflammatory drug by coexisting medical conditions of interest (CMCOI) status post-osteoarthritis diagnosis. CCAE IBM MarketScan Commercial Database, Coxibs COX-2 inhibitors, MDCR IBM MarketScan Medicare Supplemental Database, Optum CDM Optum’s de-identified Clinformatics ® Data Mart Database

    Journal: Drugs & Aging

    Article Title: Patterns of Comorbidities and Prescribing and Dispensing of Non-steroidal Anti-inflammatory Drugs (NSAIDs) Among Patients with Osteoarthritis in the USA: Real-World Study

    doi: 10.1007/s40266-024-01108-x

    Figure Lengend Snippet: Prescribing and dispensing of non-steroidal anti-inflammatory drug by coexisting medical conditions of interest (CMCOI) status post-osteoarthritis diagnosis. CCAE IBM MarketScan Commercial Database, Coxibs COX-2 inhibitors, MDCR IBM MarketScan Medicare Supplemental Database, Optum CDM Optum’s de-identified Clinformatics ® Data Mart Database

    Article Snippet: CCAE IBM MarketScan Commercial Database, Coxibs COX-2 inhibitors, MDCR IBM MarketScan Medicare Supplemental Database, Optum CDM Optum’s de-identified Clinformatics ® Data Mart Database Among patients with OA with CMCOI, post-OA diagnosis prescribing and dispensing of coxibs increased to a greater extent in the CCAE (+1.0%) and Optum CDM (+0.9%) databases than the MDCR (+0.2%) database (Fig. ).

    Techniques: Biomarker Discovery

    Prescribing and dispensing of specific non-steroidal anti-inflammatory drugs by the coexisting medical conditions of interest population, pre-osteoarthritis and post-osteoarthritis diagnosis. CCAE IBM MarketScan Commercial Database, Coxibs COX-2 inhibitors, MDCR IBM MarketScan Medicare Supplemental Database, Optum CDM Optum’s de-identified Clinformatics ® Data Mart Database

    Journal: Drugs & Aging

    Article Title: Patterns of Comorbidities and Prescribing and Dispensing of Non-steroidal Anti-inflammatory Drugs (NSAIDs) Among Patients with Osteoarthritis in the USA: Real-World Study

    doi: 10.1007/s40266-024-01108-x

    Figure Lengend Snippet: Prescribing and dispensing of specific non-steroidal anti-inflammatory drugs by the coexisting medical conditions of interest population, pre-osteoarthritis and post-osteoarthritis diagnosis. CCAE IBM MarketScan Commercial Database, Coxibs COX-2 inhibitors, MDCR IBM MarketScan Medicare Supplemental Database, Optum CDM Optum’s de-identified Clinformatics ® Data Mart Database

    Article Snippet: CCAE IBM MarketScan Commercial Database, Coxibs COX-2 inhibitors, MDCR IBM MarketScan Medicare Supplemental Database, Optum CDM Optum’s de-identified Clinformatics ® Data Mart Database Among patients with OA with CMCOI, post-OA diagnosis prescribing and dispensing of coxibs increased to a greater extent in the CCAE (+1.0%) and Optum CDM (+0.9%) databases than the MDCR (+0.2%) database (Fig. ).

    Techniques: Biomarker Discovery

    Study design. CCAE IBM MarketScan Commercial Database, CMCOI coexisting medical conditions of interest, MDCR IBM MarketScan Medicare Supplemental Database, Optum CDM Optum’s de-identified Clinformatics ® Data Mart Database, NSAIDs non-steroidal anti-inflammatory drugs, OA osteoarthritis,

    Journal: Drugs & Aging

    Article Title: Patterns of Comorbidities and Prescribing and Dispensing of Non-steroidal Anti-inflammatory Drugs (NSAIDs) Among Patients with Osteoarthritis in the USA: Real-World Study

    doi: 10.1007/s40266-024-01108-x

    Figure Lengend Snippet: Study design. CCAE IBM MarketScan Commercial Database, CMCOI coexisting medical conditions of interest, MDCR IBM MarketScan Medicare Supplemental Database, Optum CDM Optum’s de-identified Clinformatics ® Data Mart Database, NSAIDs non-steroidal anti-inflammatory drugs, OA osteoarthritis,

    Article Snippet: Databases leveraged were IBM MarketScan Medicare Supplemental Database (MDCR), IBM MarketScan Commercial Database (CCAE), and Optum’s de-identified Clinformatics ® Data Mart Database (Optum CDM).

    Techniques:

    Coexisting medical conditions of interest (CMCOI) prevalence in the osteoarthritis population. CMCOIs are not mutually exclusive. In particular, one patient can have multiple CMCOIs. CCAE IBM MarketScan Commercial Database, MDCR IBM MarketScan Medicare Supplemental Database, Optum CDM Optum’s de-identified Clinformatics ® Data Mart Database

    Journal: Drugs & Aging

    Article Title: Patterns of Comorbidities and Prescribing and Dispensing of Non-steroidal Anti-inflammatory Drugs (NSAIDs) Among Patients with Osteoarthritis in the USA: Real-World Study

    doi: 10.1007/s40266-024-01108-x

    Figure Lengend Snippet: Coexisting medical conditions of interest (CMCOI) prevalence in the osteoarthritis population. CMCOIs are not mutually exclusive. In particular, one patient can have multiple CMCOIs. CCAE IBM MarketScan Commercial Database, MDCR IBM MarketScan Medicare Supplemental Database, Optum CDM Optum’s de-identified Clinformatics ® Data Mart Database

    Article Snippet: Databases leveraged were IBM MarketScan Medicare Supplemental Database (MDCR), IBM MarketScan Commercial Database (CCAE), and Optum’s de-identified Clinformatics ® Data Mart Database (Optum CDM).

    Techniques:

    Prescribing and dispensing of non-steroidal anti-inflammatory drugs among patients with osteoarthritis, stratified by coexisting medical conditions of interest (CMCOI) status and database. CCAE IBM MarketScan Commercial Database, MDCR IBM MarketScan Medicare Supplemental Database, Optum CDM Optum’s de-identified Clinformatics ® Data Mart Database

    Journal: Drugs & Aging

    Article Title: Patterns of Comorbidities and Prescribing and Dispensing of Non-steroidal Anti-inflammatory Drugs (NSAIDs) Among Patients with Osteoarthritis in the USA: Real-World Study

    doi: 10.1007/s40266-024-01108-x

    Figure Lengend Snippet: Prescribing and dispensing of non-steroidal anti-inflammatory drugs among patients with osteoarthritis, stratified by coexisting medical conditions of interest (CMCOI) status and database. CCAE IBM MarketScan Commercial Database, MDCR IBM MarketScan Medicare Supplemental Database, Optum CDM Optum’s de-identified Clinformatics ® Data Mart Database

    Article Snippet: Databases leveraged were IBM MarketScan Medicare Supplemental Database (MDCR), IBM MarketScan Commercial Database (CCAE), and Optum’s de-identified Clinformatics ® Data Mart Database (Optum CDM).

    Techniques:

    Prescribing and dispensing of non-steroidal anti-inflammatory drug by coexisting medical conditions of interest (CMCOI) status post-osteoarthritis diagnosis. CCAE IBM MarketScan Commercial Database, Coxibs COX-2 inhibitors, MDCR IBM MarketScan Medicare Supplemental Database, Optum CDM Optum’s de-identified Clinformatics ® Data Mart Database

    Journal: Drugs & Aging

    Article Title: Patterns of Comorbidities and Prescribing and Dispensing of Non-steroidal Anti-inflammatory Drugs (NSAIDs) Among Patients with Osteoarthritis in the USA: Real-World Study

    doi: 10.1007/s40266-024-01108-x

    Figure Lengend Snippet: Prescribing and dispensing of non-steroidal anti-inflammatory drug by coexisting medical conditions of interest (CMCOI) status post-osteoarthritis diagnosis. CCAE IBM MarketScan Commercial Database, Coxibs COX-2 inhibitors, MDCR IBM MarketScan Medicare Supplemental Database, Optum CDM Optum’s de-identified Clinformatics ® Data Mart Database

    Article Snippet: Databases leveraged were IBM MarketScan Medicare Supplemental Database (MDCR), IBM MarketScan Commercial Database (CCAE), and Optum’s de-identified Clinformatics ® Data Mart Database (Optum CDM).

    Techniques: Biomarker Discovery

    Prescribing and dispensing of specific non-steroidal anti-inflammatory drugs by the coexisting medical conditions of interest population, pre-osteoarthritis and post-osteoarthritis diagnosis. CCAE IBM MarketScan Commercial Database, Coxibs COX-2 inhibitors, MDCR IBM MarketScan Medicare Supplemental Database, Optum CDM Optum’s de-identified Clinformatics ® Data Mart Database

    Journal: Drugs & Aging

    Article Title: Patterns of Comorbidities and Prescribing and Dispensing of Non-steroidal Anti-inflammatory Drugs (NSAIDs) Among Patients with Osteoarthritis in the USA: Real-World Study

    doi: 10.1007/s40266-024-01108-x

    Figure Lengend Snippet: Prescribing and dispensing of specific non-steroidal anti-inflammatory drugs by the coexisting medical conditions of interest population, pre-osteoarthritis and post-osteoarthritis diagnosis. CCAE IBM MarketScan Commercial Database, Coxibs COX-2 inhibitors, MDCR IBM MarketScan Medicare Supplemental Database, Optum CDM Optum’s de-identified Clinformatics ® Data Mart Database

    Article Snippet: Databases leveraged were IBM MarketScan Medicare Supplemental Database (MDCR), IBM MarketScan Commercial Database (CCAE), and Optum’s de-identified Clinformatics ® Data Mart Database (Optum CDM).

    Techniques: Biomarker Discovery